Galectin Therapeutics Inc. 2015 Form 10-K Summary
Business context and reporting period
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing galectin-targeting therapies for fibrotic disease and cancer. The filing covers the fiscal year ended December 31, 2015, with quarterly data for the fourth quarter ended December 31, 2015. The company had no approved products and had generated no revenue since inception.
The lead candidate, GR-MD-02, was in Phase 2 development for NASH with cirrhosis and advanced fibrosis, with additional programs in melanoma immunotherapy and plaque psoriasis. GM-CT-01 remained in preclinical development.
Financial performance, liquidity and capital structure
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue to date |
| Research and development expense | $13.1 million | $8.4 million | +56% |
| General and administrative expense | $7.0 million | $7.0 million | -1% |
| Total operating expenses | $20.1 million | $15.4 million | +30% |
| Net loss | $20.0 million | $15.8 million | Loss increased |
| Net loss applicable to common stockholders | $21.1 million | $17.0 million | Loss increased |
| Basic and diluted loss per share | $0.88 loss | $0.78 loss | Worsened |
| Net cash used in operations | $17.0 million | $12.4 million | Use increased |
| Cash and cash equivalents at year-end | $25.8 million | $29.1 million | Decreased $3.3 million |
| Total debt | $0 | $0 | No debt reported |
| Total assets | $26.4 million | $29.7 million | Decreased |
| Stockholders' equity | $18.0 million | $21.2 million | Decreased |
Margins are not meaningful because the company had no revenue. Stock-based compensation was $3.4 million in 2015. The accumulated deficit was $140.0 million at December 31, 2015.
Financing activities provided $13.7 million in 2015, including approximately $9.1 million of net proceeds from a registered direct offering and $4.6 million from at-the-market common-stock issuances. The November 2015 offering issued 4.8 million common shares and warrants to purchase approximately 3.6 million additional shares at $2.50 per share.
Material changes versus the prior comparable period
- R&D expense rose $4.7 million, primarily because Phase 2 clinical activity increased. Clinical program spending increased to $9.2 million from $3.6 million.
- Net cash used in operations increased $4.6 million as clinical development spending expanded.
- Cash declined despite equity financing, reflecting the company’s operating cash burn.
- Common shares outstanding increased to 28.8 million from 22.3 million, before considering outstanding warrants, options and preferred-stock conversions.
- Outstanding warrants increased to approximately 8.9 million from 5.5 million.
- General and administrative expense was broadly stable; lower legal and stock-based compensation costs offset higher investor-relations and insurance costs.
Guidance, outlook, risks and unusual items
- Management stated that existing unrestricted cash was expected to fund currently planned operations through March 31, 2017, after which additional financing would be required.
- Management warned that failure to raise additional capital could require significant curtailment of operations, cessation of operations or bankruptcy protection.
- NASH-FX, a 30-patient Phase 2 trial, began in 2015, with top-line data expected around the third quarter of 2016. NASH-CX, a 156-patient Phase 2 trial in NASH cirrhosis, began enrolling in June 2015, with data expected around the end of 2017.
- A 10-patient open-label psoriasis Phase 2a trial began in January 2016, with data expected around the third quarter of 2016. A second melanoma Phase 1B study using pembrolizumab was expected to begin enrolling in 2016.
- A March 2016 amendment increased the anticipated PPD budget for the NASH-CX trial to approximately $22.7 million from $14.9 million, primarily for actual patient-treatment costs and endpoint evaluation costs.
- The company remains dependent on successful clinical trials, FDA and foreign regulatory approvals, third-party clinical and manufacturing providers, intellectual-property protection and additional capital.
- Shareholder class-action and derivative lawsuits were dismissed with prejudice in December 2015, but appeals were filed. A related Nevada derivative matter was dismissed in March 2016, subject to entry of a final order and potential appeal. The company could not reasonably estimate potential losses.
- In January 2016, the company recorded a $250,000 severance obligation and $578,000 of non-cash stock compensation related to the termination of its executive chairman.
- The audited financial statements received unqualified opinions, and management and the auditors concluded that internal control over financial reporting was effective as of December 31, 2015.
Most important facts for investors to verify
- Confirm current cash runway and the timing, size and terms of required future financing.
- Track enrollment, protocol execution, safety and efficacy results for NASH-FX and NASH-CX.
- Assess the effect of the increased NASH-CX clinical-trial budget on future cash requirements.
- Review dilution from 28.8 million common shares, 8.9 million warrants, 3.3 million options and convertible preferred stock.
- Evaluate whether GR-MD-02 can demonstrate clinically meaningful efficacy beyond early safety and biomarker signals.
- Monitor regulatory milestones, manufacturing readiness and patent durability.
- Follow the appeals and final resolution of the shareholder litigation.